HIGHLIGHTS OF PRESCRIBING INFORMATION |
These highlights do not include all the information needed to use JALYN safely and effectively. See full prescribing information for JALYN.
JALYN (dutasteride and tamsulosin hydrochloride) Capsules
Initial U.S. Approval: 2010
|
RECENT MAJOR CHANGES
|
Indications and Usage, Limitations of Use (1.2) June 2011
Warnings and Precautions, Increased Risk of High-grade
Prostate Cancer (5.4) June 2011
|
INDICATIONS AND USAGE
|
JALYN is a combination of dutasteride, a 5 alpha-reductase inhibitor, and tamsulosin, an alpha adrenergic antagonist, indicated for the treatment of symptomatic benign prostatic hyperplasia (BPH) in men with an enlarged prostate. (1.1)
Limitations of Use: Dutasteride-containing products, including JALYN, are not approved for the prevention of prostate cancer. (1.2)
|
DOSAGE AND ADMINISTRATION
|
-
Take one capsule daily approximately 30minutes after the same meal each day. (2)
-
Swallow capsule whole. (2)
|
DOSAGE FORMS AND STRENGTHS
|
0.5mg dutasteride and 0.4mg tamsulosin hydrochloride. (3)
|
CONTRAINDICATIONS
|
-
Pregnancy and women of childbearing potential. (4, 5.6, 8.1)
-
Pediatric patients. (4)
-
Patients with previously demonstrated, clinically significant hypersensitivity (e.g., serious skin reactions, angioedema) to dutasteride, other 5 alpha-reductase inhibitors, tamsulosin, or any component of JALYN. (4)
|
WARNINGS AND PRECAUTIONS
|
|
以下是“全球医药”详细资料 |
|
|
|